Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2 - PubMed (original) (raw)

. 2003 Oct 24;302(5645):643-6.

doi: 10.1126/science.1088759.

Affiliations

• PMID: 14576434
• DOI: 10.1126/science.1088759

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2

Mary-Claire King et al. Science. 2003.

Abstract

Risks of breast and ovarian cancer were determined for Ashkenazi Jewish women with inherited mutations in the tumor suppressor genes BRCA1 and BRCA2. We selected 1008 index cases, regardless of family history of cancer, and carried out molecular analysis across entire families. The lifetime risk of breast cancer among female mutation carriers was 82%, similar to risks in families with many cases. Risks appear to be increasing with time: Breast cancer risk by age 50 among mutation carriers born before 1940 was 24%, but among those born after 1940 it was 67%. Lifetime risks of ovarian cancer were 54% for BRCA1 and 23% for BRCA2 mutation carriers. Physical exercise and lack of obesity in adolescence were associated with significantly delayed breast cancer onset.

PubMed Disclaimer

Comment in

• Cancer. A risky business--assessing breast cancer risk.
  Levy-Lahad E, Plon SE. Levy-Lahad E, et al. Science. 2003 Oct 24;302(5645):574-5. doi: 10.1126/science.1091465. Science. 2003. PMID: 14576407 No abstract available.
• Breast cancer risks for BRCA1/2 carriers.
  Easton DF, Hopper JL, Thomas DC, Antoniou A, Pharoah PD, Whittemore AS, Haile RW. Easton DF, et al. Science. 2004 Dec 24;306(5705):2187-91; author reply 2187-91. doi: 10.1126/science.306.5705.2187c. Science. 2004. PMID: 15622557 No abstract available.
• Breast cancer risks for BRCA1/2 carriers.
  Wacholder S, Struewing JP, Hartge P, Greene MH, Tucker MA. Wacholder S, et al. Science. 2004 Dec 24;306(5705):2187-91; author reply 2187-91. Science. 2004. PMID: 15622558 No abstract available.

Similar articles

• The lifetime risks of breast cancer in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
  Satagopan JM, Offit K, Foulkes W, Robson ME, Wacholder S, Eng CM, Karp SE, Begg CB. Satagopan JM, et al. Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):467-73. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11352856
• Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
  Simchoni S, Friedman E, Kaufman B, Gershoni-Baruch R, Orr-Urtreger A, Kedar-Barnes I, Shiri-Sverdlov R, Dagan E, Tsabari S, Shohat M, Catane R, King MC, Lahad A, Levy-Lahad E. Simchoni S, et al. Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3770-4. doi: 10.1073/pnas.0511301103. Epub 2006 Feb 28. Proc Natl Acad Sci U S A. 2006. PMID: 16537453 Free PMC article.
• Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
  Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K. Satagopan JM, et al. Clin Cancer Res. 2002 Dec;8(12):3776-81. Clin Cancer Res. 2002. PMID: 12473589
• [Clinical and molecular diagnosis of inherited breast-ovarian cancer].
  Chompret A. Chompret A. J Gynecol Obstet Biol Reprod (Paris). 2003 Apr;32(2):101-19. J Gynecol Obstet Biol Reprod (Paris). 2003. PMID: 12717301 Review. French.
• Hereditary breast and ovarian cancer in Asia: genetic epidemiology of BRCA1 and BRCA2.
  Liede A, Narod SA. Liede A, et al. Hum Mutat. 2002 Dec;20(6):413-24. doi: 10.1002/humu.10154. Hum Mutat. 2002. PMID: 12442265 Review.

Cited by

• Physical exercise during neoadjuvant chemotherapy for breast cancer as a mean to increase pathological complete response rates: Trial protocol of the randomized Neo-ACT trial.
  de Boniface J, Altena R, Haddad Ringborg C, Bolam KA, Wengström Y. de Boniface J, et al. PLoS One. 2022 Oct 13;17(10):e0274804. doi: 10.1371/journal.pone.0274804. eCollection 2022. PLoS One. 2022. PMID: 36227931 Free PMC article.
• Micro-RNAs in breast cancer progression and metastasis: A chromatin and metabolic perspective.
  Sikder S, Bhattacharya A, Agrawal A, Sethi G, Kundu TK. Sikder S, et al. Heliyon. 2024 Sep 20;10(19):e38193. doi: 10.1016/j.heliyon.2024.e38193. eCollection 2024 Oct 15. Heliyon. 2024. PMID: 39386816 Free PMC article. Review.
• BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality.
  Li X, Zou L. Li X, et al. J Clin Invest. 2024 Jul 15;134(14):e181062. doi: 10.1172/JCI181062. J Clin Invest. 2024. PMID: 39007266 Free PMC article. Review.
• Design and validation of a next generation sequencing assay for hereditary BRCA1 and BRCA2 mutation testing.
  Kang HP, Maguire JR, Chu CS, Haque IS, Lai H, Mar-Heyming R, Ready K, Vysotskaia VS, Evans EA. Kang HP, et al. PeerJ. 2016 Jun 28;4:e2162. doi: 10.7717/peerj.2162. eCollection 2016. PeerJ. 2016. PMID: 27375968 Free PMC article.
• Two novel frameshift mutations in BRCA2 gene detected by next generation sequencing in a survey of Spanish patients of breast cancer.
  Hernan I, Mañé B, Borràs E, de Sousa Dias M, Llort G, Yagüe C, Gamundi MJ, Arcusa À, Carballo M. Hernan I, et al. Clin Transl Oncol. 2015 Jul;17(7):576-80. doi: 10.1007/s12094-014-1271-x. Epub 2015 Jan 14. Clin Transl Oncol. 2015. PMID: 25586199

Publication types

MeSH terms

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Other Literature Sources

  • H1 Connect - Access expert opinions and insights on biomedical research.
  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal